Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $58.02
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 15, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 15, 26 | Chardan Capital | maintain | Buy | Buy |
| Sep 1, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 31, 26 | Chardan Capital | maintain | Buy | Buy |
| Aug 31, 26 | RBC Capital | maintain | Outperform | Outperform |
| Aug 6, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 30, 26 | B. Riley Securities | maintain | Buy | Buy |
| Jul 27, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 23, 26 | Morgan Stanley | maintain | Overweight | Overweight |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 33.06 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 29.08 | Oscillator | Neutral |
| Williams %R (14) | -70.24 | Oscillator | Neutral |
| MACD (12, 26, 9) | -3.96 (Hist 0.51) | Oscillator | Buy |
| Average Directional Index (14) | 37.85 (+DI 15.2 / -DI 32.1) | Trend | Strong Sell |
| EMA 20 | 61.56 | MA | Strong Sell |
| SMA 20 | 60.90 | MA | Strong Sell |
| EMA 50 | 68.63 | MA | Strong Sell |
| SMA 50 | 72.62 | MA | Strong Sell |
| SMA 200 | 71.87 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | ARWR | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -25.9x | -582.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -16.5x | EPS est. -3.52 | Discount |
| Price / Book | 17.9x | 11.5x | Elevated |
| Price / Sales | 12.2x | 146.4x | Discount |
| EV / EBITDA | -67.4x | -12.7x | Elevated |
| Return on equity | -60.5% | — | Weak |
| Gross margin | 100.0% | -6.6% | Below hist. |
| Debt / Equity | 1.86 | 1.41 | Levered |
| Piotroski / Altman Z | 3/9 | Z 2.57 | Grey zone |
Discounted cash flow model
| 10-Q | Aug 4, 2026 | 2026-08-04 16:02:09 | View |
| SC 13G/A | Jul 31, 2026 | 2026-07-31 11:20:53 | View |
| SC 13G/A | Jul 27, 2026 | 2026-07-27 16:25:25 | View |
| 4 | Jun 17, 2026 | 2026-06-17 21:44:15 | View |
| 3 | Jun 17, 2026 | 2026-06-17 21:44:09 | View |
| 8-K | Jun 16, 2026 | 2026-06-16 16:02:56 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 18, 26 | Olukotun Adeoye Y | director | S-Sale | 2,000 @ $86.96 | $173.9K |
| Aug 18, 26 | Perry Michael S | director | S-Sale | 11,600 @ $87.30 | $1.01M |
| Jun 15, 26 | Cohen Matthew Gregory | director | A-Award | 11,882 | — |
| Jun 15, 26 | Cohen Matthew Gregory | director | 0 | — | |
| May 12, 26 | Lu Hongbo | director | S-Sale | 2,970 @ $76.88 | $228.3K |
| Apr 22, 26 | Apel Daniel Joseph | officer: Chief Financial Officer | S-Sale | 3,208 @ $70.11 | $224.9K |
| Apr 22, 26 | Apel Daniel Joseph | officer: Chief Financial Officer | S-Sale | 1,157 @ $70.45 | $81.51K |
| Apr 22, 26 | Apel Daniel Joseph | officer: Chief Financial Officer | S-Sale | 8,730 @ $71.92 | $627.9K |
Stock news · updated daily
DBV Technologies (NASDAQ: DBVT - Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ: ARWR - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations. Risk and Volatility DBV Technologies has a beta
Arrowhead Pharmaceuticals, Inc. exceeded expectations with ARO-MAPT phase 1 results, achieving up to 85% CSF tau reduction and validating its subcutaneous CNS siRNA platform. ARWR plans to expand its CNS pipeline, initiating two new ARO-MAPT phase 2 trials and advancing four additional CNS candidates into the clinic by end of 2027. Recent milestones include strong Redemplo phase 3 data, positive ARO-DIMER-PA results, and FDA STAR program entry for Redemplo, supporting a robust long-term growth outlook.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | -1.28 | -1.36 | Miss -6.3% | $75.25M |
| May 7, 2026 | -1.09 | -0.93 | Beat 14.7% | $73.74M |
| Feb 5, 2026 | 0.60 | 0.22 | Miss -63.3% | $264.0M |
| Nov 25, 2025 | -0.11 | -0.18 | Miss -61.3% | $256.5M |
| Aug 7, 2025 | -0.94 | -1.26 | Miss -34.0% | $27.77M |
| May 12, 2025 | -0.06 | 2.75 | Beat 4683.3% | $542.7M |